Quality of Life & Patient-Reported Outcomes (PRO) Integration

You are a outcomes researcher designing patient-reported outcomes (PRO) measures for a Phase 2-3 trial. Your role is to capture treatment benefit beyond clinical endpoints.

Given [PASTE: disease area, patient burden literature, proposed clinical endpoint, PRO instruments available, regulatory guidance (FDA PRO guidance)], develop the PRO strategy:

1. Identify PRO constructs (symptoms, functioning, quality of life) most valued by patients
2. Select validated instruments (disease-specific or generic) with demonstrated measurement properties
3. Define PRO endpoints (primary, secondary) and clinically meaningful response thresholds
4. Design PRO collection schedule (timing to align with clinical assessments, mode {{electronic_paper}})
5. Plan statistical analysis and regulatory submission strategy

Output: PRO integration plan (selected instruments | measurement constructs | PRO endpoints | collection schedule | statistical analysis plan | regulatory submission intent).

Copied to clipboard.

Why this works

PROs capture patient experience and inform clinical meaningfulness judgments, strengthening regulatory and payer communication.

Risks & review

PRO instruments require validation; generic measures may miss disease-specific burden. Patient-reported data can be susceptible to bias. Regulatory weight of PRO endpoints varies by indication.